OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).
- DOI
- 10.1038/s41416-026-03558-z
- Published
- 2026 Jul 18
- Container
- British journal of cancer
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41416-026-03558-z,
title = {OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).},
author = {Grünwald V and Alt J and Tometten M and Hänel M and Ivanyi P and Schuch G and Klinghammer K and Gutsche K and Hasenkamp J and Hapke G and Mänz M and Mogler C and Hahn D},
year = {2026},
journal = {British journal of cancer},
doi = {10.1038/s41416-026-03558-z},
url = {https://doi.org/10.1038/s41416-026-03558-z}
}RIS
TY - JOUR TI - OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117). AU - Grünwald V AU - Alt J AU - Tometten M AU - Hänel M AU - Ivanyi P AU - Schuch G AU - Klinghammer K AU - Gutsche K AU - Hasenkamp J AU - Hapke G AU - Mänz M AU - Mogler C AU - Hahn D PY - 2026 JO - British journal of cancer DO - 10.1038/s41416-026-03558-z UR - https://doi.org/10.1038/s41416-026-03558-z ER -
APA
V, G., J, A., M, T., M, H., P, I., G, S., K, K., K, G., J, H., G, H., M, M., C, M., & D, H. (2026). OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).. British journal of cancer. https://doi.org/10.1038/s41416-026-03558-z
Source records
- pubmed · retrieved 2026-09-26T06:37:35.876Z